<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396849</url>
  </required_header>
  <id_info>
    <org_study_id>4689673</org_study_id>
    <secondary_id>5R01HL048522</secondary_id>
    <nct_id>NCT02396849</nct_id>
  </id_info>
  <brief_title>Modulation Of Airway Reactivity With Chronic Mechanical Strain</brief_title>
  <official_title>Modulation Of Airway Reactivity With Chronic Mechanical Strain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the use of a machine called CPAP will help children&#xD;
      with asthma breathe better. CPAP is a machine that produces airflow to help people with&#xD;
      breathing problems. To use it, you will wear a mask connected by a hose to the CPAP machine.&#xD;
      We believe that use of CPAP may be a treatment for children with asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the previous funding period of this project, our laboratory demonstrated that chronic&#xD;
      mechanical strain imposed on the airways in vivo using continuous positive airway pressure&#xD;
      (CPAP) results in a dramatic reduction in airway reactivity in vivo in mice, ferrets and&#xD;
      rabbits1-3. Lungs, airways and airway smooth muscle (ASM) tissues isolated from CPAP-treated&#xD;
      animals studied in vitro exhibited lower responsiveness to bronchoconstrictors1-3. We also&#xD;
      observed this suppression of airway responsiveness by chronic mechanical strain in a rabbit&#xD;
      model of allergic asthma5. These animal studies led to a small clinical trial in which adults&#xD;
      with asthma were treated with nocturnal CPAP for 1 week. CPAP caused a significant reduction&#xD;
      in airway reactivity in these patients6. This novel approach for treating airway&#xD;
      hyper-reactivity is currently being evaluated in a NIH multi-center Phase II clinical trial&#xD;
      of adults with mild to moderate asthma (U01 HL108730).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2)</measure>
    <time_frame>baseline (visit 1) and 4 weeks (visit 2)</time_frame>
    <description>The change in airway reactivity measured prior to and after 4 weeks of either CPAP or SHAM treatment. Methacholine bronchial challenge was performed using the 5-breath protocol (DeVilbiss646 with KoKo dosimeter: 9 μL/breath) with quadrupling concentrations starting with 0.0625 mg/mL and continuing until FEV1 decreased by 20% (PC20) or Methacholine concentration of 16 mg/mL was inhaled.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Airway Inflammation From Baseline (Visit 1) and 4 Weeks (Visit 2)</measure>
    <time_frame>baseline (visit 1) and 4 weeks (visit 2)</time_frame>
    <description>Airway Inflammation assessed as the change in the percentage eosinophils in the induced sputum measured prior to and after 4 weeks of Continuous Positive Airway Pressure (CPAP) or sham CPAP treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Continuous Positive Airway Pressure (CPAP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of a CPAP machine for at least 5 days per week for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Positive Airway Pressure (CPAP) Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Use of a sham CPAP machine for at least 5 days per week for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure (CPAP)</intervention_name>
    <description>Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
    <arm_group_label>Continuous Positive Airway Pressure (CPAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure (CPAP) Sham</intervention_name>
    <description>Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
    <arm_group_label>Continuous Positive Airway Pressure (CPAP) Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 8-17 yrs olds with severe asthma (N=120) will be recruited from the Pediatric&#xD;
             High Risk Asthma Clinic and Pulmonary Clinics at Riley Hospital for Children at&#xD;
             Indiana University Health.&#xD;
&#xD;
          -  Severe asthma will be defined by the need for medication therapies following steps 4-6&#xD;
             according to the National Institutes of Health's Asthma Care Quick Reference,&#xD;
             September 2012 or high dose of inhaled corticosteroids&#xD;
&#xD;
          -  On a stable regimen of asthma medications for at least 8 weeks prior to enrollment&#xD;
             without systemic corticosteroids for ≥ 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obese (&gt;95% predicted BMI)&#xD;
&#xD;
          -  Congenital heart disease or chronic lung disease&#xD;
&#xD;
          -  History of pneumothorax&#xD;
&#xD;
          -  Inability to perform pulmonary function testing&#xD;
&#xD;
          -  Oxygen saturation &lt;93%&#xD;
&#xD;
          -  forced expiratory volume at one second (FEV1) &lt;70% predicted&#xD;
&#xD;
          -  Provocative concentration causing a 20% drop in FEV1 from baseline (PC20) ≥16 mg/ml of&#xD;
             methacholine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Tepper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <results_first_submitted>January 5, 2021</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Robert Tepper</investigator_full_name>
    <investigator_title>Robert Tepper</investigator_title>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02396849/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>25 were excluded based on screening criteria, two subjects (one in each group) were lost to follow-up, two (one in each group) did not tolerate the equipment and two (one in each group) did not undergo Methacholine challenge at V2 due to the presence of asthma symptoms.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Continuous Positive Airway Pressure (CPAP)</title>
          <description>Use of a CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP: Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Continuous Positive Airway Pressure (CPAP) Sham</title>
          <description>Use of a sham CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP Sham: Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not tolerate intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CPAP</title>
          <description>Use of a CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP: Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>CPAP Sham</title>
          <description>Use of a sham CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP Sham: Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" spread="2.5"/>
                    <measurement group_id="B2" value="11.7" spread="2.5"/>
                    <measurement group_id="B3" value="11.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Methacholine Bronchial Challenge</title>
          <description>Methacholine bronchial challenge was performed using the 5-breath protocol (DeVilbiss646 with KoKo dosimeter: 9 μL/breath) with quadrupling concentrations starting with 0.0625 mg/mL and continuing until forced expiratory volume at one second (FEV1) decreased by 20% or Methacholine concentration of 16 mg/mL was inhaled.</description>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="4.5"/>
                    <measurement group_id="B2" value="3.2" spread="4.3"/>
                    <measurement group_id="B3" value="3.09" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2)</title>
        <description>The change in airway reactivity measured prior to and after 4 weeks of either CPAP or SHAM treatment. Methacholine bronchial challenge was performed using the 5-breath protocol (DeVilbiss646 with KoKo dosimeter: 9 μL/breath) with quadrupling concentrations starting with 0.0625 mg/mL and continuing until FEV1 decreased by 20% (PC20) or Methacholine concentration of 16 mg/mL was inhaled.</description>
        <time_frame>baseline (visit 1) and 4 weeks (visit 2)</time_frame>
        <population>One subject in each group did not undergo Methacholine challenge at V2 due to the presence of asthma symptoms</population>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>Use of a CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP: Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CPAP Sham</title>
            <description>Use of a sham CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP Sham: Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2)</title>
          <description>The change in airway reactivity measured prior to and after 4 weeks of either CPAP or SHAM treatment. Methacholine bronchial challenge was performed using the 5-breath protocol (DeVilbiss646 with KoKo dosimeter: 9 μL/breath) with quadrupling concentrations starting with 0.0625 mg/mL and continuing until FEV1 decreased by 20% (PC20) or Methacholine concentration of 16 mg/mL was inhaled.</description>
          <population>One subject in each group did not undergo Methacholine challenge at V2 due to the presence of asthma symptoms</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.6"/>
                    <measurement group_id="O2" value="3.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="8.9"/>
                    <measurement group_id="O2" value="4.3" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Airway Inflammation From Baseline (Visit 1) and 4 Weeks (Visit 2)</title>
        <description>Airway Inflammation assessed as the change in the percentage eosinophils in the induced sputum measured prior to and after 4 weeks of Continuous Positive Airway Pressure (CPAP) or sham CPAP treatment.</description>
        <time_frame>baseline (visit 1) and 4 weeks (visit 2)</time_frame>
        <population>The overall success rate in obtaining quality sputum samples was 57%; however, only 10 CPAP and 12 sham subjects had quality samples at both study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Positive Airway Pressure (CPAP)</title>
            <description>Use of a CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP: Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Continuous Positive Airway Pressure (CPAP) Sham</title>
            <description>Use of a sham CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP Sham: Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Airway Inflammation From Baseline (Visit 1) and 4 Weeks (Visit 2)</title>
          <description>Airway Inflammation assessed as the change in the percentage eosinophils in the induced sputum measured prior to and after 4 weeks of Continuous Positive Airway Pressure (CPAP) or sham CPAP treatment.</description>
          <population>The overall success rate in obtaining quality sputum samples was 57%; however, only 10 CPAP and 12 sham subjects had quality samples at both study visits.</population>
          <units>Percentage of sputum eosinophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="10.1"/>
                    <measurement group_id="O2" value="3.9" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="6.4"/>
                    <measurement group_id="O2" value="5.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>Adverse event were described as an asthma exacerbation requiring oral corticosteroids during the study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>CPAP</title>
          <description>Use of a CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP: Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>CPAP Sham</title>
          <description>Use of a sham CPAP machine for at least 5 days per week for 28 days&#xD;
CPAP Sham: Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma exacerbation treated with oral corticosteroids</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We evaluated only children with moderate-severe asthma, the results cannot be extrapolated to children with mild or moderate asthma. A major limitation of our study was the limited number of subjects we could recruit from a single pediatric center. Our evaluation of airway inflammation was limited to induced sputum rather than bronchoalveolar lavage, which would not have been an acceptable risk in our children.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christina Tiller</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-044-4522</phone>
      <email>ctiller@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

